Edesa Biotech, Inc. (NASDAQ:EDSA) Financings

Edesa Biotech, Inc.

Financings

RaiseDate
Public offering of common shares (or pre-funded warrants) and accompanying common share warrants
Announced: about US$25M · US$5.5 a share · Warrants at US$7.5 · Guggenheim Securities
Dealers: Guggenheim Securities (lead)
Use of proceeds: General corporate purposes, possibly including working capital, capital expenditures, and research, development and manufacturing expenses
Aug 20, 2026
Private placement of common shares
Announced: about US$3.5M · US$4.69 a share
Buyers: Chief Executive Officer of Edesa (common shares at $5.21 per common share)
Insiders: Edesa's Chief Executive Officer is an investor in the PIPE, buying at $5.21 per common share
Use of proceeds: Advancing the vitiligo program and paridiprubart, plus working capital and general corporate purposes
Jun 11, 2026
At-the-market programme of common shares
Tranche closed: US$3.4M raised
Dec 12, 2025
Private placement of series B-1 convertible preferred shares and common shares
Closed: US$15M raised · US$1.92 a share
Buyers: Velan Capital (led the placement); Nantahala Capital; Rubric Capital Management LP; Stonepine Capital Management; Broadfin Holdings LLC
Insiders: Officers and directors purchased approximately $1.1 million of the securities sold
Use of proceeds: Advance EB06 CXCL10 antibody into a Phase 2 study in nonsegmental vitiligo, plus working capital and general corporate purposes
Feb 13, 2025
Private placement of securities
Closed: US$1.5M raised
Buyers: Entity affiliated with Edesa's Chief Executive Officer and Founder ($1.5 million in gross proceeds under a securities purchase agreement)
Insiders: An entity affiliated with the Chief Executive Officer and Founder provided the $1.5 million under a securities purchase agreement
Dec 13, 2024
At-the-market programme of common shares
Tranche closed: US$600,000 raised
Dec 13, 2024

Read by 6ix AI from the company's releases